Loading…
Apimeds Pharmaceuticals US, Inc. is projected to decline to $0.5895 by 2027, a -18% move from its current price of $0.72. APUS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.6737 | $0.72 | $0.7695 | 0.00% |
| Jul 14 | $0.6554 | $0.72 | $0.791 | 0.00% |
| Jul 15 | $0.6416 | $0.72 | $0.8079 | 0.00% |
| Jul 16 | $0.6303 | $0.72 | $0.8225 | 0.00% |
| Jul 17 | $0.6205 | $0.72 | $0.8355 | 0.00% |
| Jul 18 | $0.6117 | $0.72 | $0.8474 | 0.00% |
| Jul 19 | $0.6038 | $0.72 | $0.8586 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6038 | $0.72 | $0.8586 | 0.00% |
| Week 2 | $0.5614 | $0.72 | $0.9235 | 0.00% |
| Week 3 | $0.5308 | $0.72 | $0.9766 | 0.00% |
| Week 4 | $0.5064 | $0.72 | $1.02 | 0.00% |
| Week 5 | $0.4858 | $0.72 | $1.07 | 0.00% |
| Week 6 | $0.4679 | $0.72 | $1.11 | +0.01% |
| Week 7 | $0.452 | $0.72 | $1.15 | +0.01% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. It operates as a subsidiary of Inscobee., Inc.
It is categorized in Healthcare. APUS trades in the health sector as a small-cap asset with a focus on digital treasury infrastructure.
APUS is currently trading at $0.7425, with a market cap of $11.21M and a rank of 5105. This places the stock among lower-profile healthcare names with a very small market footprint. The current price and sector positioning set a base for the year-ahead and multi-year forecasts.
The forecast presents a wide range of potential outcomes over the coming years. In the near term, the average price remains close to the current level, while the longer horizon shows meaningful upside culminating in an average around $2.58 by 2050 with a max up to $5.93 and a theoretical return of 247.1%. This suggests a high-variance, bullish longer-term scenario alongside notable near-term volatility.
A major floor 74.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 111.1% above — a clean break opens room to run.
A major ceiling 2761.1% above — clearing it would confirm fresh momentum.
Key APUS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APUS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7586 | Sell | $0.7615 | Sell |
| MA 10 | $0.8303 | Sell | $0.8248 | Sell |
| MA 20 | $0.9663 | Sell | $0.9586 | Sell |
| MA 50 | $1.31 | Sell | $2.00 | Sell |
| MA 100 | $5.09 | Sell | $5.04 | Sell |
| MA 200 | $12.48 | Sell | $9.64 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.46 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -99.99 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -19.10 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.18 | Sell |
| Awesome (5,34) | -0.38 | Sell |
| Ultimate (7,14,28) | 12.86 | Buy |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.69 | Buy |
| ADX (14) | 34.95 | Sell |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is neutral, with RSI(14) at 30 and a mixed momentum setup guiding near-term moves. The stock sits below the 50-day moving average ($1.37) while far from the 200-day average ($12.76), indicating limited upward pressure on a short horizon.
Support sits at $0.743 and resistance at $1.52, framing a tight 30-day range between $0.4592 and $1.20. Given the neutral sentiment, traders may look for a break above resistance or below support to confirm the next directional move.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.72 | $0.72 | $0.9737 | 0% | Neutral | |
| $0.4107 | $0.5895 | $0.9173 | -18% | Bearish | |
| $0.4476 | $0.6937 | $1.16 | -4% | Neutral | |
| $0.5448 | $0.9024 | $1.60 | +25% | Bullish | |
| $0.4943 | $0.8705 | $1.61 | +21% | Bullish | |
| $0.5353 | $0.9991 | $1.92 | +39% | Bullish | |
| $0.4857 | $0.9588 | $1.91 | +33% | Bullish | |
| $0.3505 | $0.7311 | $1.50 | +2% | Neutral | |
| $0.3737 | $0.8227 | $1.74 | +14% | Neutral | |
| $0.4007 | $0.8904 | $1.93 | +24% | Bullish | |
| $0.5521 | $1.23 | $2.82 | +70% | Bullish | |
| $1.13 | $2.51 | $5.78 | +249% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.72 | $0.72 | $0.9323 | +0.00% |
| August 2026 | $0.633 | $0.775 | $0.9933 | +7.64% |
| September 2026 | $0.5781 | $0.7201 | $0.9458 | -7.09% |
| October 2026 | $0.5491 | $0.6942 | $0.9306 | -3.60% |
| November 2026 | $0.5645 | $0.7228 | $0.9854 | +4.12% |
| December 2026 | $0.5428 | $0.7033 | $0.9737 | -2.70% |
Click any year to see its month-by-month APUS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Apimeds Pharmaceuticals US, Inc.'s 2026 outlook centres on $0.72, within a $0.72 to $0.9737 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, APUS could reach as high as $0.9173, with a base case around $0.5895 and support toward $0.4107 — roughly -18% from $0.72. Expect choppier, lower action through this leg of the cycle.
Expect APUS to range from $0.4476 to $1.16 through 2028. The $0.6937 average target implies a -4% move from current prices. That is up +18% on the projected 2027 average. Price action looks broadly range-bound.
The APUS price prediction for 2029 points to an average of $0.9024 (low $0.5448, high $1.60) — a potential gain of +25% on today's $0.72. Buyers look set to stay in control over this stretch.
In 2030, APUS is projected to trade between $0.4943 and $1.61, averaging $0.8705 — a potential gain of +21% from today's $0.72. That is -4% versus the projected 2029 average. Momentum favours further upside here.
Apimeds Pharmaceuticals US, Inc.'s 2031 outlook centres on $0.9991, within a $0.5353 to $1.92 range. That is up +15% on the projected 2030 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, APUS could reach as high as $1.91, with a base case around $0.9588 and support toward $0.4857 — roughly +33% from $0.72. Momentum favours further upside here.
Expect APUS to range from $0.3505 to $1.50 through 2033. The $0.7311 average target implies a +2% move from current prices. That is -24% versus the projected 2032 average. A consolidation phase looks the most probable path here.
The APUS price prediction for 2034 points to an average of $0.8227 (low $0.3737, high $1.74) — a potential gain of +14% on today's $0.72. Price action looks broadly range-bound.
In 2035, APUS is projected to trade between $0.4007 and $1.93, averaging $0.8904 — a potential gain of +24% from today's $0.72. That is up +8% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Apimeds Pharmaceuticals US, Inc.'s 2040 outlook centres on $1.23, within a $0.5521 to $2.82 range. That is up +38% on the projected 2035 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2050, APUS could reach as high as $5.78, with a base case around $2.51 and support toward $1.13 — roughly +249% from $0.72. Buyers look set to stay in control over this stretch.
Investing $1,000 in APUS today (≈ 1,388.888889 APUS) could be worth
$3,491.78
+$2,491.78 (+249%) by 2050 · US Dollar
Based on the average projected APUS price of $2.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APUSwould be worth at today's price.
$1,000 invested in APUS on Jul 10, 2025 (≈ 55.248618 APUS) would be worth
$39.78
-$960.22 (-96.0%) today · 0.04× · US Dollar
Based on a APUS entry price of $18.1 vs. today's $0.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.9 | $800 | -20.0% |
| 1 month ago | $1.29 | $558.14 | -44.2% |
| 3 months ago | $1.88 | $382.98 | -61.7% |
| 6 months ago | $18.7 | $38.5 | -96.1% |
| 1 year ago | $18.1 | $39.78 | -96.0% |
| All time (1.2y) ago | $22 | $32.73 | -96.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APUS forecast.
Our base-case forecast reaches $1.40 around 2050.
Implied market cap at $1.40: $21.13M
Over the multi-year horizon, the forecast shows a shift toward bullish sentiment from the late 2020s onward. The year-by-year view includes a flat or modest near-term return in 2026 (avg $0.7425, ROI 0, sentiment NEUTRAL) followed by a dip in 2027 (avg $0.6128, ROI -17.5, sentiment BEARISH) and a return to uptrends in 2028 (avg $0.7198, ROI -3.1, sentiment NEUTRAL).
From 2029 onward, the outlook improves with a 2029 avg of $0.9237 and ROI 24.4 (sentiment BULLISH), continuing into 2030 with avg $0.9013 and ROI 21.4 (BULLISH) and 2031 with avg $1.04 and ROI 39.6 (BULLISH). The gains extend through 2032 (avg $0.9808, ROI 32.1) and 2035 (avg $0.9169, ROI 23.5), reflecting a sustained bullish tilt.
Longer-dated years show meaningful upside, including 2040 with avg $1.27 and ROI 71.5 (BULLISH), and 2050 with avg $2.58 and ROI 247.1 (BULLISH). The 2050 max projection reaches $5.93. These figures imply higher volatility and dependence on evolving market drivers while painting a broadly constructive long-term path, with risk factors reflected in earlier years where projections dip and sentiment turns negative at times.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.9013 with a min of $0.5097 and a max of $1.67, and a projected ROI of 21.4% with bullish sentiment.
Yes. The forecast for 2050 lists a max of $5.93, an average of $2.58, and a projected ROI of 247.1% with bullish sentiment.
APUS is at $0.7425 with a market cap of $11.21M.
The 30-day picture is neutral with RSI(14) at 30, a 50-day SMA of $1.37, and a 200-day SMA of $12.76. Support is at $0.743 and resistance at $1.52, with a 30-day range from $0.4592 to $1.20.
The long-term view is bullish from 2029 onward, with multiple years showing positive returns (e.g., 2029 ROI 24.4%, 2030 ROI 21.4%, 2040 ROI 71.5%, and 2050 ROI 247.1%). However, there are earlier years with bearish or neutral signals, indicating the investment carries significant volatility and uncertainty.
Apimeds Pharmaceuticals US, Inc. Community Discussion
0Share your Apimeds Pharmaceuticals US, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.